Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
05/2003
05/27/2003US6569463 Encapsulation coat includes different combinations of pharmaceutical active ingredients, hydrophilic and lipophilic surfactants, and triglycerides
05/27/2003US6569462 Spraying tablet with dry particles of drug and/or excipient, electrostatic attraction occurs between them; coating with polymeric membranes having controlled release, gastroresistance, targeted release or taste masking properties
05/27/2003US6569460 Film-coated tablet for improved upper gastrointestinal tract safety
05/27/2003US6569459 Method of administration of paclitaxel-plasma protein formulation
05/27/2003US6569457 Enteric coated pharmaceutical tablet and method of manufacturing
05/27/2003US6569455 Quick-release extrudates, method for preparing the same and compositions obtained from said extrudates
05/27/2003US6569453 No enteric layers and are suitable for oral administration
05/27/2003US6569450 Lipid-conjugated polyamide compounds and related compositions and methods thereof
05/27/2003US6569443 Topical treatment or prevention of ocular infections
05/27/2003US6569441 Therapeutic inhibitor of vascular smooth muscle cells
05/27/2003US6569426 Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity
05/27/2003US6569424 A probiotic formulation of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799); containing at least one volatile fraction (VF) of a plant extract
05/27/2003US6569410 Sun protection compositions containing UV protection factors and esters of hydroxycarboxylic acids and alk(en)yl oligoglycosides
05/27/2003US6569406 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
05/27/2003US6569355 Chiral compounds, and their use as chiral dopants for the preparation of cholesteric liquid-crystalline compositions
05/27/2003CA2387361C Crystal form 0 and form ii of clarithromycin and uses thereof
05/27/2003CA2387356C Crystal form 0 and form i of clarithromycin and uses thereof
05/27/2003CA2310960C Phosphate-binding polymers for oral administration
05/27/2003CA2277274C Crystal form 0 of clarithromycin
05/27/2003CA2199747C 2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof
05/27/2003CA2176229C Improved interferon polymer conjugates
05/27/2003CA2174072C Hydrogel-forming, self-solvating absorbable polyester block copolymers, and methods for use thereof
05/27/2003CA2110119C Antiinflammatory and analgesic gel preparation
05/22/2003WO2003042344A2 Apo2 ligand/trail formulations
05/22/2003WO2003042300A1 Method for preparing gels
05/22/2003WO2003042277A1 The polyester containing active drugs and having amino acids in the main chain, and its preparation method
05/22/2003WO2003042251A1 Chitosan compositions
05/22/2003WO2003042244A2 Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
05/22/2003WO2003041757A2 Catheter injectable depot compositions and uses thereof
05/22/2003WO2003041744A2 Protease enzyme inhibitors
05/22/2003WO2003041743A1 Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification
05/22/2003WO2003041742A1 Nutraceutical composition
05/22/2003WO2003041729A1 Ptp1b inhibitors and ligands
05/22/2003WO2003041716A1 Dosage unit comprising a prostaglandin analog for treating constipation
05/22/2003WO2003041705A1 Oral dosage form of a sulfonamide prodrug such as parecoxib
05/22/2003WO2003041702A1 Production of pure stereoisomers of tricyclo[5.2.1.02.6]-dec-9-yl xanthogenate and medicaments therefrom
05/22/2003WO2003041699A1 Storage stable thyroxine active drug formulations and methods for their production
05/22/2003WO2003041696A1 Methods and compositions for use of (s)-bisoprolol
05/22/2003WO2003041690A2 Three-dimensional suspension printing of dosage forms
05/22/2003WO2003041689A1 Biocompatible polymer blends and uses thereof
05/22/2003WO2003041688A1 Methods for treatment of inflammatory diseases
05/22/2003WO2003041686A2 Improved therapy for topical diseases
05/22/2003WO2003041685A1 Injectable depot composition
05/22/2003WO2003041684A2 Injectable depot compositions and uses thereof
05/22/2003WO2003041683A2 Orodispersible tablets containing fexofenadine
05/22/2003WO2003041680A1 Topical compositions containing enzymes stabilized with inhibitors
05/22/2003WO2003041656A2 Soluble drug extended release system
05/22/2003WO2003041651A2 Allatoin-containing skin cream
05/22/2003WO2003041648A2 High-concentration lidocaine compositions and methods for their preparation
05/22/2003WO2003041642A2 Polymeric thiol-linked prodrugs employing benzyl elimination systems
05/22/2003WO2003041637A2 Lyophilized monoclonal antibody compositions
05/22/2003WO2003041632A2 Eutectic-based self-nanoemulsified drug delivery system
05/22/2003WO2003041500A1 Topical formulations of natamycin/pimaricin
05/22/2003WO2003020763A3 Soluble t cell receptor
05/22/2003WO2003020253A3 Pharmaceutical compositions for the treatment of asthma
05/22/2003WO2003013498A3 Nitrate ester-cyclodextrin complexes for treating diseases, particularly coronary diseases
05/22/2003WO2003011115A3 Peptide-based multimeric targeted contrast agents
05/22/2003WO2002100353A3 Cd10-activated prodrug compounds
05/22/2003WO2002097116A3 Delivery system for nucleic acids
05/22/2003WO2002076425A3 Manufacturing dissolvable dosage forms
05/22/2003WO2002074339B1 Deveice and method for the photodynamic diagnosis of tumor tissue
05/22/2003WO2002058737A3 Multivalent meningococcal polysaccharide-protein conjugate vaccine
05/22/2003WO2002056831A3 Immunogenic proteoliposomes, and uses thereof
05/22/2003WO2002045685A3 Cristallizable/non crystallizable polymer composites
05/22/2003WO2002041844A9 Chemotherapeutic composition using nanocrystalline calcium phosphate paste
05/22/2003WO2001068708A9 Human and humanized fap-alpha-specific antibodies
05/22/2003US20030096992 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
05/22/2003US20030096879 Gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters or mixtures thereof
05/22/2003US20030096874 For prophylaxis and therapy of respiratory diseases asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease
05/22/2003US20030096872 Acetaminophen compositions
05/22/2003US20030096868 Sertraline oral concentrate
05/22/2003US20030096863 Method for inhibition or treatment of colon tumorigenesis
05/22/2003US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite
05/22/2003US20030096845 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
05/22/2003US20030096840 Granule formulation
05/22/2003US20030096839 Methods for preparing pharmaceutical formulations
05/22/2003US20030096834 Pharmaceutical compositions
05/22/2003US20030096822 Comprises moxidectin, praziquantel, benzyl alcohol, ethanol, colloidal silicon dioxide, surfactant, and oil; veterinary medicine
05/22/2003US20030096791 Taste masking of highly water-soluble drugs
05/22/2003US20030096774 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
05/22/2003US20030096770 Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
05/22/2003US20030096765 Aromatic esters; cytotoxic agents; antitumor agents
05/22/2003US20030096761 Angiotensin converting enzyme (ACE) and/or neutral endopeptidase (NEP); organic acids and salts thereof, sodium lauryl sulfate and palmitoyl carnitine enhancers used in treating cardiovascular disorders
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096743 p-Amidobenzylethers in drug delivery agents
05/22/2003US20030096739 Nuclear receptor-mediated introduction of a PNA into cell nuclei
05/22/2003US20030096417 Vaccination against feline immunodeficiency virus
05/22/2003US20030096400 N-terminally chemically modified protein compositions and methods
05/22/2003US20030096354 Synthetic polypeptide ligand for use in the treatment of cardiovascular, tumor, viral and hypertensive disorders
05/22/2003US20030096352 Nucleotide sequences coding polypeptides for use in the treatment and prevention of viral and bacterial disease
05/22/2003US20030096350 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096338 Protein conjugate for use in the treatment of blood disorder
05/22/2003US20030096280 Targeted transfection of cells using a biotinylated dendrimer
05/22/2003US20030096266 Hydrophobic biopolymer for use in the treatment of infections, blood, inflammatory and muscular disorders
05/22/2003US20030096259 In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs), homogeneous VLP and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
05/22/2003US20030096027 Alpha acid, (e.g., humulone) or beta acid (e.g., lupulone)
05/22/2003US20030096012 Film-forming powder, compositions containing it, methods for their preparation and their uses
05/22/2003US20030096010 Random copolymer of an N-alkyl- or N,N-dialkyl(meth)acrylamide and a hydrophilic comonomer; may be a graft polymer; drug delivery
05/22/2003US20030096005 Pharmaceutical excipient having improved compressibility
05/22/2003US20030096002 Delivery system for biological component
1 ... 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 ... 1712